- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03413423
Post Acute Cardiac Event Smoking (PACES) Study
Secondary Prevention Following Acute Coronary Syndrome Using Integrated Smoking Cessation and Mood Management
Summary of the Project :
Quitting smoking following acute coronary syndrome (ACS) can reduce mortality up to 50%. However, depression and smoking are highly co-morbid and depressed mood may interfere with cessation and independently predicts mortality. Thus, a single, integrated treatment for both smoking and depression could be highly effective in reducing post-acute coronary syndrome mortality. Behavioral Activation (BA) is a well established treatment for depression and has recently shown promise as a treatment for smoking cessation. The investigators systematically developed an intervention integrating gold standard smoking cessation counseling with existing BA based mood management techniques for post-ACS smokers; Behavioral Activation Treatment for Cardiac Smokers (BAT-CS).
Objective: For this R01 the investigators will evaluate the efficacy of using a single, integrated treatment that targets both depressed mood and smoking (BAT-CS).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrew Busch, PhD
- Phone Number: 612-873-6681
- Email: andrew.busch@hcmed.org
Study Contact Backup
- Name: Michelle L Chrastek, MPH
- Phone Number: 612-873-5364
- Email: michelle.chrastek@hcmed.org
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- hospital inpatients with an ACS diagnosis documented in medical record within the past 30 days
- smoked equal or greater than 1 cigarette per day before being hospitalized
- age of 18-75 years
- English fluency
- willing to consider quitting smoking at discharge
- has a telephone or is willing to use a study issued cell phone
- willing to consent to all study procedures.
Exclusion Criteria:
- limited mental competency
- presence of severe mental illness that would interfere with participation or suicidality
- expected discharge to hospice or greater than 50% chance of 6 month mortality per risk calculator
- currently attending counseling for depression or smoking cessation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAT-CS
Participants will receive standard smoking cessation plus Behavioral Activation based mood management.
Will be offered the nicotine patch if medically cleared.
|
All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome.
Participants will be randomized 1 week after discharge.
Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge.
The first will be up to one hour and will be conducted in person.
The next 4 sessions will occur by phone and will take about 30 minutes.
Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques.
Participants will be offered the nicotine patch if medically cleared.
Other Names:
|
Active Comparator: Smoking Cessation and Health & Wellness
Participants will receive standard smoking cessation plus health and wellness education.
Will be offered the nicotine patch if medically cleared.
|
All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome.
Participants will be randomized 1 week after discharge.
Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge.
The first will be up to one hour and will be conducted in person.
The next 4 sessions will occur over the phone and will take about 30 minutes.
Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education.
Participants will be offered the nicotine patch if medically cleared.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
7-day point prevalence abstinence from smoking
Time Frame: 12 Months
|
Self-report of no smoking, not even a puff, for 7 days; then Bio-chemically confirmed with saliva cotinine or by carbon monoxide in a breath sample
|
12 Months
|
Depression Symptoms
Time Frame: 12 Months
|
The 9 item Patient Health Questionnaire (PHQ-9) ranges from 0-27 with higher scores indicating higher depression symptoms.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Continuous Abstinence From Smoking Since Hospital Discharge
Time Frame: 12 Months
|
No smoking, not even a puff, since hospital discharge
|
12 Months
|
Time to Smoking Relapse
Time Frame: 12 Months
|
Time in days to first relapse (i.e., smoking on 7 consecutive days or smoking in 2 consecutive 7 day periods), which were determined through timeline follow back interviewing.
|
12 Months
|
Time to Smoking Lapse
Time Frame: 12 Months
|
Time in days to first lapse (i.e., first puff of a cigarette) after discharge, which were determined through timeline follow back interviewing.
|
12 Months
|
Depressed mood
Time Frame: The 10 item Center for Epidemiologic Studies Depression Scale ranges from 0-30 with higher scores indicating higher depression symptoms.
|
10 Item Center for Epidemiologic Studies Depression Scale (CESD)
|
The 10 item Center for Epidemiologic Studies Depression Scale ranges from 0-30 with higher scores indicating higher depression symptoms.
|
Positive Affect
Time Frame: 12 Months
|
As measured by the 10 item Positive Affect Negative Affect Scales (PANAS).
The positive affect scale on the PANAS ranges from 5-25 with higher scores indicating greater positive affect.
|
12 Months
|
Negative Affect
Time Frame: 12 Months
|
As measured by the 10 item Positive Affect Negative Affect Scales (PANAS).
The negative affect scale on the PANAS ranges from 5-25 with higher scores indicating greater negative affect.
|
12 Months
|
Systolic and Diastolic Blood Pressure
Time Frame: 12 Months
|
Resting Systolic and Diastolic Blood Pressure
|
12 Months
|
Blood Bio-markers
Time Frame: 12 Months
|
HDL, LDL, High Sensitivity C-reactive protein, and Fibrinogen
|
12 Months
|
Major adverse cardiac events (MACE) and all cause mortality
Time Frame: 5 years
|
Time in days to MACE or all cause mortality.
MACE = non-fatal myocardial infarction (using standard American Heart Association definitions), hospitalization for unstable angina, or urgent coronary revascularization.
|
5 years
|
Health Related Quality of Life
Time Frame: 12 Months
|
12-Item Short Form Health Survey (SF-12)
|
12 Months
|
Treatment Acceptability
Time Frame: 12 weeks
|
Client Satisfaction Questionnaire
|
12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-4375
- 1R01HL136327 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on BAT-CS
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnTobacco Use | Acute Coronary SyndromeUnited States
-
University of OxfordCompleted
-
Virginia Polytechnic Institute and State UniversityRecruiting
-
Helsinki University Central HospitalOdense University Hospital; University of Oslo; Sahlgrenska University Hospital... and other collaboratorsCompletedResistant HypertensionDenmark, Sweden, Finland, Norway
-
London School of Hygiene and Tropical MedicineMedical Research Council; University of OxfordCompleted
-
Yan JinXijing Hospital; Tang-Du HospitalUnknownJoint Diseases | Osteochondritis | Osteochondritis DissecansChina
-
Eximis SurgicalTerminatedLaparoscopic Gynecological SurgeryUnited States
-
CorrectSequence Therapeutics Co., LtdFirst Affiliated Hospital of Guangxi Medical UniversityNot yet recruiting
-
PATHUnited States Agency for International Development (USAID); Centers for Disease... and other collaboratorsCompletedMalariaUnited States, Mozambique